Latest Series C+ Funding Rounds
Later-stage rounds, from Series C onwards, for companies expanding products, distribution and operations.
- Rounds
- 422 All time
- Disclosed funding
- $108.3B 381 disclosed amounts
- Median round
- $120M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| S Combines travel booking with co-branded credit cards and mobile payments | $63M | Series CSeries C+ | Fintech | India | Investors | |
| N NourishCompany profile Provides AI-native metabolic health care with dietitians and virtual medical services Provides AI-native metabolic health care with dietitians and virtual medical services | $100M | Series CSeries C+ | Healthtech | United States | Investors | |
| CV Cagent VascularCompany profile Develops endovascular serration and lithotripsy technologies for peripheral and coronary artery disease Develops endovascular serration and lithotripsy technologies for peripheral and coronary artery disease | $41M | Series DSeries C+ | Healthtech | United States | Investors | |
| T Provides AI-powered weather intelligence for organizations | $210M | Series FSeries C+ | AI | United States | Investors | |
| SC Sigma ComputingCompany profile Provides a spreadsheet-style agentic analytics platform for enterprises to build AI apps on cloud data warehouses Provides a spreadsheet-style agentic analytics platform for enterprises to build AI apps on cloud data warehouses | $80M | Series ESeries C+ | AI | United States | Investors | |
| G GradiantCompany profile Provides advanced water and wastewater treatment solutions for AI, semiconductor, and industrial sectors Provides advanced water and wastewater treatment solutions for AI, semiconductor, and industrial sectors | Undisclosed | Series ESeries C+ | Climate tech | United States | Investors | |
| AB Accro BioscienceCompany profile Clinical-stage medicines targeting inflammation and regulated cell-death pathways in immune-mediated disease. Clinical-stage medicines targeting inflammation and regulated cell-death pathways in immune-mediated disease. | $50M | Series CSeries C+ | Biotech | United States | Investors | |
| BM Butterfly MedicalCompany profile Develops a minimally invasive implantable device to treat benign prostatic hyperplasia in men Develops a minimally invasive implantable device to treat benign prostatic hyperplasia in men | $21M | Series CSeries C+ | Healthtech | Israel | Investors | |
| AI Anduril IndustriesCompany profile Anduril Industries builds autonomous defense systems and Lattice software connecting sensors, platforms and military command workflows. Anduril Industries builds autonomous defense systems and Lattice software connecting sensors, platforms and military command workflows. | $5B | Series HSeries C+ | Defense tech | United States | Investors | |
| O OishiiCompany profile Oishii grows strawberries indoors using vertical farming, robotics and automation. Oishii grows strawberries indoors using vertical farming, robotics and automation. | $150M | Series CSeries C+ | Agritech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1Andreessen Horowitz (a16z)
Labelbox, Valon, Devoted Health
35rounds3led - 2Sequoia Capital
Blacksmith, Abby Care, Instinct
31rounds2led - 3Lightspeed
Enveda, Snorkel AI, Profound
28rounds3led - 4General Catalyst
Legora, Modal Labs, Varda
27rounds0led - 5Y Combinator (YC)
Blacksmith, Jeeves, Hubble Network
21rounds0led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.